BASELINE (UNTREATED) RISK OF HOSPITALIZATION AND MORTALITY IN PATIENTS WITH SPECIFIC COMORBID HIGH-RISK CONDITIONS WHO ARE ELIGIBLE FOR NIRMATRELVIR/RITONAVIR TREATMENT: A SYSTEMATIC LITERATURE REVIEW EXPANSION STUDY

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/baseline-untreated-risk-of-hospitalization-and-mortality-in-patients-with-specific-comorbid-high-risk-conditions-who-are-eligible-for-nirmatrelvir-ritonavir-treatment-a-systematic-literature-review-expansion-study

Tendai Mugwagwa, MSc 1; David Campbell, PharmD, MS 2; Athira Ajith, PharmD 3; Nikolina Boskovic, MPH 4; Sarah C. Katsandres, MPH 4; Cynthia L. Gong, PharmD, PhD 4; Tobias Bergroth, PhD 5; Maria C. Pein, MSc 6; Kristen Migliaccio-Walle, BS 4

Mar 6, 2026